All Whitepapers

Genpact’s latest report, Life Sciences and Healthcare in the Age of Instinct, explores three major trends shaping the future of healthcare.

As precision medicine grows, so, too, does demand for biobanking services, offering both strategic and financial investors a significant opportunity for value creation.

The Pharmaceutical Executive® APEX Awards feature some of today’s best creative work in the pharmaceutical industry. Come and see how you did, along with other agencies, at our live virtual event on September 9.

For pharma companies engaged in digital transformation, LabVantage Pharma is a purpose-built, pre-validated LIMS to bring your labs along the transformation journey.

This whitepaper looks at the requirements for High Throughput Screening, High Content Screening and Surface Plasmon Resonance and makes suggestions for how to make these processes more flexible and repeatable.

This white paper describes how digitizing medicines can drive patient engagement, reduce non-adherence, and enhance supply chain visibility.

Life sciences transformations rarely fail because of what was in the plan. They fail because of what was not. Explore five trends that will determine their success in coming years.

Gain actionable insights from Lash Group experts, leveraging 30+ years of experience launching new programs to help you ensure patient support success.

In this case study, learn how to increase payer engagement, drive awareness, monitor competition, and leverage insights to enhance strategic plans and launch success.

With bigger patient access and affordability barriers given the new normal of COVID-19, see why field services are more important than ever. Read now.

This whitepaper discusses the importance of patient support programs and why a robust risk mitigation plan is critical to ensure that patients receive their therapy during crises.

In today’s fast-paced marketplace and complicated regulatory environment, operating in the life sciences industry can bring a variety of challenges. From raising capital or addressing pricing pressures to prioritizing development efforts or managing third-party risks, the landscape of Biopharma Finance is changing.

With the future of face-to-face field sales uncertain, how can pharma ensure product messaging reaches the right healthcare audiences and, ultimately, patients?

Hospitals represent a critical access point for many therapeutics. Whether a therapeutic is indicated for use exclusively in a hospital or in both inpatient and outpatient settings, hospitals are key points of drug initiation or switching. To gain access to this channel, pharma companies must understand the needs and differences of hospital systems.

Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.